LYRA · Lyra Therapeutics, Inc.
$0.25
+0.00 (+0.00%)
At close · Aug 13
Going-concern doubt
— flagged Mar 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern”View the 10-K filed Mar 31, 2026
Market Cap
$443,720
Shares
1.77M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$398K
-74.1%
FY2025
Net Income
-$28.92M
+69%
FY2025
Operating Margin
-7794.47%
-1513.6pp
FY2025
Diluted EPS
-$18.62
+74%
FY2025
Operating Cash Flow
-$28.86M
+58.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| $398K | $1.53M | $1.56M | $1.36M | $285K | — | — | |
| $18.41M | $43.77M | $48.03M | $38.8M | $29.69M | $12.52M | $12.03M | |
| $11.54M | $18.5M | $19.06M | $17.56M | $14.21M | $9.69M | $4.49M | |
| $1.47M | $10.9M | — | — | — | — | — | |
| $31.42M | $97.88M | $68.68M | $57.67M | $43.9M | $22.21M | $16.52M | |
| -$31.02M | -$96.35M | -$67.12M | -$56.31M | -$43.62M | -$22.21M | -$16.52M | |
| -7794.47% | -6280.83% | -4308.09% | -4131.03% | -15303.51% | — | — | |
| $1.13M | $2.95M | $4.5M | $1.04M | $102K | $82K | $213K | |
| $2.11M | $2.95M | $4.5M | $1.04M | $102K | $82K | $213K | |
| -$28.91M | -$93.4M | -$62.62M | -$55.27M | -$43.51M | — | — | |
| $11K | $39K | $59K | $13K | $0 | $0 | $0 | |
| -$28.92M | -$93.44M | -$62.68M | -$55.28M | -$43.51M | -$22.13M | -$16.31M | |
| -7266.08% | -6090.94% | -4023.11% | -4055.61% | -15267.72% | — | — | |
| -$28.92M | -$93.44M | -$62.68M | -$55.28M | -$43.51M | -$22.24M | -$16.62M | |
| -$28.92M | -$93.47M | -$62.66M | -$55.27M | -$43.51M | -$22.13M | -$16.31M | |
| USD/shares | -$18.62 | -$71.75 | -$63.00 | -$91.50 | -$167.50 | — | — |
| USD/shares | -$18.62 | -$71.75 | -$63.00 | -$91.50 | -$167.50 | — | — |
| shares | 1.55M | 1.3M | 996.09K | 604.71K | 259.72K | 171.8K | 4041.86 |
| shares | 1.55M | 1.3M | 996.09K | 604.71K | 259.72K | 171.8K | 4041.86 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.24×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 40 similar-size Biotechnology companies (of 545 listed).